Annexon, Inc.
Public company- Headquarters
- BRISBANE, California
- Ticker
- ANNX
- CIK
- 0001528115
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| member of the BoardMuneer Satter | Aug 10, 2026 | Departed |
| Class II directorMark S. Blumenkranz, M.D., M.S.S. | Aug 10, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- ACADIA PHARMACEUTICALS INC
Executive Vice President, Head of Research and Development departs: Elizabeth H.Z. Thompson, Ph.D.
- KYNTRA BIO, INC.
Class III director appointed: Andrew E. Singer, MBA
- BIOMARIN PHARMACEUTICAL INC
WARN notice: Novato, CA
- CORCEPT THERAPEUTICS INC
President of Corcept Endocrinology departs: Sean Maduck
- Executive departure
member of the Board departs: Muneer Satter
Muneer Satter, member of the Board of Annexon, Inc., resigns the role, effective August 10, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 10, 2026Role: member of the Board
- Executive appointment
Class II director appointed: Mark S. Blumenkranz, M.D., M.S.S.
Mark S. Blumenkranz, M.D., M.S.S. was named Class II director of Annexon, Inc., effective August 10, 2026. Mark S. Blumenkranz, M.D., M.S.S. succeeds Muneer Satter. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 10, 2026Role: Class II director
Last verified Nov 9, 2026